Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALDX Aldeyra Therapeutics	$2.22 +0.9%	$2.85	$1.14 ▼ $7.20	$132.97M	0.92	787,328 shs	410,852 shs
AMRN Amarin	$11.29 -0.6%	$9.92	$7.08 ▼ $17.58	$233.78M	0.66	76,162 shs	55,366 shs
ANAB AnaptysBio	$20.90 +3.8%	$19.57	$12.21 ▼ $41.31	$614.04M	-0.2	607,949 shs	1.71 million shs
MCRB Seres Therapeutics	$7.05 -2.5%	$9.85	$6.53 ▼ $30.60	$61.56M	2.89	146,444 shs	67,071 shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALDX Aldeyra Therapeutics	+0.91%	-1.33%	-19.57%	-64.98%	-41.42%
AMRN Amarin	-0.62%	+2.82%	+9.40%	+2.45%	-32.81%
ANAB AnaptysBio	+3.83%	+0.43%	-2.02%	+27.44%	-10.53%
MCRB Seres Therapeutics	-2.49%	-8.44%	-24.27%	-51.58%	-62.08%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALDX Aldeyra Therapeutics	2.5689 of 5 stars	3.5	3.0	0.0	2.6	1.7	0.6
AMRN Amarin	0.1914 of 5 stars	1.0	2.0	0.0	1.9	0.0	0.0
ANAB AnaptysBio	2.8404 of 5 stars	4.4	1.0	0.0	3.0	1.7	0.6
MCRB Seres Therapeutics	2.8742 of 5 stars	2.9	1.0	4.6	2.0	0.8	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALDX Aldeyra Therapeutics	3.00	Buy	$9.50	327.93% Upside
AMRN Amarin	2.00	Hold	$7.00	-38.00% Downside
ANAB AnaptysBio	2.70	Moderate Buy	$40.38	93.18% Upside
MCRB Seres Therapeutics	1.80	Reduce	$73.67	944.92% Upside

Current Analyst Ratings Breakdown

Latest ANAB, ALDX, MCRB, and AMRN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/28/2025	ANAB AnaptysBio	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$54.00 ➝ $90.00
5/19/2025	ALDX Aldeyra Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
5/8/2025	MCRB Seres Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$1.25 ➝ $6.00
5/6/2025	ANAB AnaptysBio	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$52.00 ➝ $54.00
5/1/2025	ANAB AnaptysBio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$40.00 ➝ $40.00
4/17/2025	AMRN Amarin	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sell ➝ Sell	$20.00 ➝ $7.00
4/7/2025	ALDX Aldeyra Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$11.00 ➝ $9.00
4/4/2025	ALDX Aldeyra Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
3/26/2025	ANAB AnaptysBio	Johnson Rice Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
3/20/2025	MCRB Seres Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00 ➝ $25.00
3/14/2025	MCRB Seres Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sell ➝ Sell	$20.00 ➝ $15.00

(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALDX Aldeyra Therapeutics	N/A	N/A	N/A	N/A	$2.04 per share	N/A
AMRN Amarin	$214.11M	1.09	N/A	N/A	$1.35 per share	8.36
ANAB AnaptysBio	$111.87M	5.49	N/A	N/A	$3.32 per share	6.30
MCRB Seres Therapeutics	$126.33M	0.49	N/A	N/A	($0.35) per share	-20.14

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALDX Aldeyra Therapeutics	-$37.54M	-$0.97	N/A	N/A	N/A	N/A	-43.01%	-33.62%	8/7/2025 (Estimated)
AMRN Amarin	-$59.11M	-$3.64	N/A	N/A	N/A	-16.33%	-7.22%	-4.96%	7/30/2025 (Estimated)
ANAB AnaptysBio	-$163.62M	-$4.85	N/A	N/A	N/A	-289.75%	-287.94%	-37.25%	8/4/2025 (Estimated)
MCRB Seres Therapeutics	-$113.72M	-$4.60	N/A	N/A	N/A	N/A	N/A	-55.08%	8/12/2025 (Estimated)

Latest ANAB, ALDX, MCRB, and AMRN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	ALDX Aldeyra Therapeutics	-$0.25	-$0.17	+$0.08	-$0.17	($0.80) million	N/A
5/7/2025	Q1 2025	AMRN Amarin	-$0.06	-$0.04	+$0.02	-$0.04	$50.75 million	N/A
5/7/2025	Q1 2025	MCRB Seres Therapeutics	-$0.67	-$2.24	-$1.57	$3.75	$10.00 million	N/A
5/5/2025	Q1 2025	ANAB AnaptysBio	-$1.30	-$1.28	+$0.02	-$1.28	$15.27 million	$27.77 million
3/12/2025	Q4 2024	AMRN Amarin	-$1.20	-$2.40	-$1.20	-$0.12	$32.37 million	$62.31 million
3/6/2025	Q4 2024	ALDX Aldeyra Therapeutics	$0.03	-$0.27	-$0.30	-$0.27	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALDX Aldeyra Therapeutics	N/A	N/A	N/A	N/A	N/A
AMRN Amarin	N/A	N/A	N/A	N/A	N/A
ANAB AnaptysBio	N/A	N/A	N/A	N/A	N/A
MCRB Seres Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALDX Aldeyra Therapeutics	0.18	6.80	6.80
AMRN Amarin	N/A	3.23	2.11
ANAB AnaptysBio	N/A	10.23	10.23
MCRB Seres Therapeutics	N/A	1.12	1.12

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALDX Aldeyra Therapeutics	59.71%
AMRN Amarin	22.25%
ANAB AnaptysBio	N/A
MCRB Seres Therapeutics	59.34%

Insider Ownership

Company	Insider Ownership
ALDX Aldeyra Therapeutics	9.60%
AMRN Amarin	3.30%
ANAB AnaptysBio	33.50%
MCRB Seres Therapeutics	4.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALDX Aldeyra Therapeutics	15	59.90 million	54.49 million	Optionable
AMRN Amarin	360	20.71 million	402.62 million	Optionable
ANAB AnaptysBio	100	29.38 million	20.17 million	Optionable
MCRB Seres Therapeutics	330	8.73 million	162.03 million	Optionable

ANAB, ALDX, MCRB, and AMRN Headlines

Recent News About These Companies

Seres Therapeutics, Inc. (NASDAQ:MCRB) Given Consensus Recommendation of "Reduce" by Brokerages

May 29 at 3:19 AM | marketbeat.com

Seres Therapeutics Presents Expanded SER-155 Exploratory Biomarker Data at 2025 ASCO Annual Meeting

May 27 at 7:00 AM | globenewswire.com

Seres Therapeutics (MCRB) Upgraded to Buy: What Does It Mean for the Stock?

May 23, 2025 | zacks.com

Seres Therapeutics (NASDAQ:MCRB) Shares Pass Below Two Hundred Day Moving Average - Here's Why

May 19, 2025 | marketbeat.com

Wall Street Analysts Believe Seres Therapeutics (MCRB) Could Rally 713.09%: Here's is How to Trade

May 16, 2025 | zacks.com

StockNews.com Upgrades Seres Therapeutics (NASDAQ:MCRB) to Hold

May 11, 2025 | marketbeat.com

Seres Therapeutics (NASDAQ:MCRB) Rating Increased to Hold at StockNews.com

May 11, 2025 | marketbeat.com

Seres Therapeutics' (MCRB) Neutral Rating Reaffirmed at Chardan Capital

May 10, 2025 | marketbeat.com

Seres Therapeutics, Inc. (NASDAQ:MCRB) Q1 2025 Earnings Call Transcript

May 9, 2025 | insidermonkey.com

Chardan Capital Downgrades Seres Therapeutics (MCRB)

May 9, 2025 | msn.com

Seres Therapeutics, Inc. (MCRB) Q1 2025 Earnings Call Transcript

May 7, 2025 | seekingalpha.com

Seres Therapeutics reports Q1 EPS $3.75, consensus $1.97

May 7, 2025 | msn.com

Seres Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates

May 7, 2025 | globenewswire.com

Seres Therapeutics Q1 2025 Earnings Preview

May 6, 2025 | msn.com

Why Seres Therapeutics, Inc.’s (MCRB) Stock Is Down 5.09%

May 6, 2025 | aaii.com

Seres Therapeutics, Inc. (NASDAQ:MCRB) Given Consensus Recommendation of "Hold" by Brokerages

May 5, 2025 | marketbeat.com

Seres Therapeutics (NASDAQ:MCRB) Stock Passes Below 50-Day Moving Average - Here's What Happened

May 4, 2025 | marketbeat.com

Seres Therapeutics (NASDAQ:MCRB) Cut to Sell at StockNews.com

May 3, 2025 | marketbeat.com

Seres Therapeutics (MCRB) Projected to Post Quarterly Earnings on Wednesday

May 2, 2025 | marketbeat.com

Seres Therapeutics Presents Data at the 2025 Digestive Disease Week Conference Highlighting the Potential for Live Biotherapeutics to Treat Inflammatory and Immune Diseases

April 29, 2025 | globenewswire.com

Petri Dish: Boston Scientific CFO retires; Biotech undergoes 1-for-20 reverse stock split

April 24, 2025 | bizjournals.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANAB, ALDX, MCRB, and AMRN Company Descriptions

Aldeyra Therapeutics NASDAQ:ALDX

$2.22 +0.02 (+0.91%)

Closing price 05/28/2025 04:00 PM Eastern

Extended Trading

$2.22 -0.01 (-0.23%)

As of 04:01 AM Eastern

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.

Amarin NASDAQ:AMRN

$11.29 -0.07 (-0.62%)

Closing price 05/28/2025 04:00 PM Eastern

Extended Trading

$11.30 +0.01 (+0.09%)

As of 05/28/2025 05:30 PM Eastern

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

AnaptysBio NASDAQ:ANAB

$20.90 +0.77 (+3.83%)

Closing price 05/28/2025 04:00 PM Eastern

Extended Trading

$20.92 +0.02 (+0.07%)

As of 05/28/2025 05:26 PM Eastern

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Seres Therapeutics NASDAQ:MCRB

$7.05 -0.18 (-2.49%)

Closing price 05/28/2025 04:00 PM Eastern

Extended Trading

$7.09 +0.04 (+0.62%)

As of 05/28/2025 07:56 PM Eastern

Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time